In this edition of Target Research we look into the techniques and tools used by clinicians to make a diagnosis – from muscle biopsies to genetic sequencing. We also have an article on ataluren (or Translarna as it is now known), looking at the European Medicines Agency’s recommendation that the drug should be given conditional approval for Duchenne muscular dystrophy. Finally, we feature the work we are doing in partnership with other organisations and charities and some of the exciting results of this work.
Friends of MDUK receive our Campaign newsletter, Target MD, a copy of our annual Impact Report and other benefits – for only £15 a year by Direct Debit. Visit the Friends of MDUK page to find out more and join today!